Neovii, Tel Aviv University partner for COVID-19 vaccine

By The Science Advisory Board staff writers

May 13, 2020 -- Israeli firm Ramot has inked a license agreement with Neovii, a Swiss-based biopharmaceutical company, for the research and development of a COVID-19 vaccine.

Ramot is Tel Aviv University's technology transfer company. University researchers have been working with coronaviruses for over 15 years, and shortly after SARS-CoV-2 emerged they began reconstituting a receptor binding motif as the basis for a new vaccine.

Under the agreement, Neovii will hold exclusive rights to develop and commercialize an epitope-based vaccine platform for the rapid discovery of a novel COVID-19 vaccine. The vaccine under development aims to reconstruct the coronavirus's receptor binding motif within the spike protein. The company will work to manufacture and deliver a commercial product to the general population on an accelerated timeline.

NIH leadership discusses COVID-19 vaccine collaborations
Public-private partnerships could help meet the unprecedented need to manufacture and distribute safe and effective COVID-19 vaccines around the globe,...
ABL Europe to manufacture Themis SARS-CoV-2 vaccine in France
Biopharmaceutical company Themis and contract development and manufacturing organization ABL Europe announced that they have signed an agreement to manufacture...
Inovio expands manufacturing for COVID-19 vaccine
Inovio has partnered with German contract manufacturer Richter-Helm BioLogics to produce large-scale quantities of Inovio's investigational DNA vaccine.

Copyright © 2020

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter